-
Hims & Hers Health: Analysts remain bearish
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $30, 'we do think that this will be a slight headwind to HIMS'
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), 'We think HIMS will not make any margin on dispensing of Wegovy'
-
Hims and Hers (HIMS) PT Lowered to $25 at Citi Amid Valuation Destruction During 2025
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $27, 'highly unlikely that this appeal changes much'
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $27, 'Court Delivers Another Blow to Tirzepatide Compounders'
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $27, 'We view this as Novo taking a direct shot at HIMS'
-
Hims and Hers (HIMS) PT Raised to $27 at Citi, Maintains Sell 'as we await a better entry point and more details on growth outside GLP-1s'
-
Citi Downgrades Hims and Hers (HIMS) to Sell
-
Hims and Hers (HIMS) PT Raised to $24 at Citi
-
Citi Reiterates Neutral Rating on Hims and Hers (HIMS)
-
Citi on Hims and Hers (HIMS) Post Lilly (LLY) News: 'Single-dose Zepbound Vials a Shot Across the Bow for the Compounders'
-
These stocks are near-term opportunity to invest in the GLP-1 space
-
Citi Downgrades Hims and Hers (HIMS) to Neutral
-
Citi Reiterates Buy Rating on Hims and Hers (HIMS)
-
Citi Comments on Hims and Hers (HIMS) Weight Loss Program
-
Hims & Hers to Announce Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
-
Hims & Hers Health, Inc. to Participate at Citi’s 2022 Virtual Healthcare Conference
-
Hims & Hers Health to Present at Upcoming Financial Conferences
-
Hims & Hers Health, Inc. to Participate in Upcoming Investor Conference
-
Hims & Hers Health (HIMS) Starts Trading on NYSE Following Completion of SPAC Merger

